Pro 140

The next class of antiviral agents for the treatment of HIV

About CytoDyn

CytoDyn is committed to enhancing the lives of men and women with HIV. We focus on developing new therapies that provide flexibility and freedom to people across the globe who are living with HIV. 

Read More About CytoDyn

PRO 140

Our lead product, PRO 140, belongs to a new class of HIV/AIDS therapeutics that protects healthy cells from viral infection.  PRO 140 has several potential benefits including less frequent dosing and minimal side effects that distinguish it from currently used HIV treatments.

Read More About PRO 140

CCR5 and Cancer

Our CMO Dr. Richard Pestell, MD, PhD, MB, BS, FACP, FRACP, FAAAS, MBA, is a world renowned oncologist and researcher. Dr. Pestell has played an instrumental role in identifying the role of CCR5 in cancer indications, and has worked to develop CCR5 technology

Learn More About CCR5 and Dr. Pestell's Research
Watch how PRO 140 combats HIV
Watch how PRO 140 combats HIV
View Video
CytoDyn’s Expanded Strategic Direction
CytoDyn’s Expanded Strategic Direction

As described by Nader Pourhassan, Ph.D., President & CEO, and Richard Pestell, M.D., Ph.D., Chief Medical Officer

View Video